Clinically meaningful improvements
in motor function in later-onset SMA

Some patients with later-onset (Types 2 and 3) spinal muscular atrophy (SMA) treated with SPINRAZA® (nusinersen) achieved improvements in motor function.1

Primary endpoint: change from baseline in Hammersmith Functional Motor Scale—Expanded (HFMSE)1

Chart showing patients treated with SPINRAZA improved in HFMSE score
Chart showing patients treated with SPINRAZA improved in HFMSE score

Baseline:
SPINRAZA: 22.4
Untreated: 19.9
LSM=least squares mean; SE=standard error.

Patients treated with SPINRAZA demonstrated a clinically meaningful change (≥3-point increase) in HFMSE total score from baseline, improving in ≥2 motor skills.1

Emma
age 7

Later-onset (Type 3) SMA
treated with SPINRAZA

Emma
age 7

Later-onset (Type 3) SMA
treated with SPINRAZA

Individual results may vary based on several factors, including severity of disease, initiation of treatment, and duration of therapy.